Text anzeigen (PDF) - bei DuEPublico

Literatur 105
97) Matsubara M, Yamagata H, Kamino K, Nomura T, Kohara K, Kondo I, Miki T (2001): Genetic association
between Alzheimer disease and the alpha-synuclein gene. Dement Geriatr Cogn Disord 12,
106-9.
98) Matsui T, Morikawa Y, Tojo M, Okamura N, Maruyama M, Hirai H, Chiba H, Matsushita S, Higuchi
S, Arai H, Sasaki H (2001): Cathepsin D-Polymorphism not associated with Alzheimer's disease in
Japanese. Ann Neurol 49, 544-5.
99) Mattila KM, Axelman K, Rinne JO, Blomberg M, Lehtimaki T, Laippala P, Roytta M, Viitanen M,
Wahlund L, Winblad B, Lannfelt L (2000a): Interaction between estrogen receptor 1 and the epsilon4
allele of apolipoprotein E increases the risk of familial Alzheimer's disease in women. Neurosci Lett.
282, 45-8.
100) Mattila KM, Rinne JO, Roytta M, Laippala P, Pietila T, Kalimo H, Koivula T, Frey H, Lehtimaki T
(2000b): Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions
with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease
with coexisting Alzheimer pathology. J Med Genet. 37, 766-70.
101) McCusker SM, Curran MD, Dynan KB, McCullagh CD, Urquhart DD, Middleton D, Patterson CC,
McIlroy SP, Passmore AP (2001): Association between polymorphism in regulatory region of gene
encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a casecontrol
study. Lancet 357, 436-9.
102) McIlroy SP, Vahidassr MD, Savage DA, Patterson CC, Lawson JT, Passmore AP (1999a): Risk of
Alzheimer's disease is associated with a very low-density lipoprotein receptor genotype in Northern Ireland.
Am J Med Genet 88, 140-4.
103) McIlroy SP, Dynan KB , McGleenon BM, Lawson JT, Passmore AP (1999b): Cathepsin D-Gene exon
2 polymorphism and sporadic Alzheimer's disease. Neurosci Lett 273, 140-1.
104) McKhann G, Drachman D , Folstein M, Katzman R, Price D, Stadlan EM (1984): Clinical diagnosis
of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department
of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-44.
105) Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000): Plasma and cerebrospinal
fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 57,
100-5.
106) Menzer G, Muller-Thomsen T, Meins W, Alberici A, Binetti G, Hock C, Nitsch RM, Stoppe G, Reiss
J, Finckh U (2001): Non-repliCation of association between Cathepsin D-Genotype and late onset
Alzheimer disease. Am.J Med Genet. 105, 179-82.
107) Meyer MR, Tschanz JT , Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, Breitner JC
(1998): APOE-Genotype predicts when--not whether--one is predisposed to develop Alzheimer disease.
Nature Genetics 19, 321-2.
108) Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle
G, Berg L (1991): The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II.
Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-86.
109) Montoya SE, Aston CE, DeKosky ST, Kamboh MI, Lazo JS, Ferrell RE (1998): Bleomycin hydrolase
is associated with risk of sporadic Alzheimer's disease. Nat Genet. 17, 211-2. Erratum in: Nat Genet
18, 404.
110) Mortimer JA, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Rocca WA (1991): Head trauma
as a risk factor for Alzheimer´s disease: a collaborative re-analysis of case-control studies. EURO-
DERM Risk factors research group. Int J Epidemiol. 20, S28-35.
111) Muller U, Kins S (2002): APP on the move. Trends Mol. Med. 8, 152-155.